The Lilly MDR-TB Partnership exists to save lives by preventing and treating multi-drug resistant tuberculosis (MDR-TB) - a terrible disease that afflicts millions of people in some of the poorest regions of the world. Our partnership takes an innovative approach, drawing on a large group of public and private organizations to bring a comprehensive range of resources, expertise, and services to bear against MDR-TB - in ways that are tailored to local circumstances and needs on the ground.

Welcome from John Lechleiter

John LechleiterEvery year, nearly 2 million people die from tuberculosis, a curable disease. Poor adherence to the necessary drug regimen and interrupted treatment are widespread problems in resource-constrained countries. These problems not only keep patients from being cured of the disease but also can lead to multi-drug resistant strains of TB, which require even longer and more complex treatment. Conservative estimates indicate that about 500,000 new cases of MDR-TB arise every year, and that the average person with the disease infects up to 15 other people during his or her lifetime. Clearly, this pandemic requires a massive mobilization of people and resources to address it.

Our partners are private and public healthcare professionals, academics, patient- and community-advocacy groups, international organizations, and producers of medicines in developing regions. We focus in particular on the hardest-hit countries: China, India, Russia, and South Africa. The Lilly MDR-TB Partnership seeks to fight the disease by sharing drug-manufacturing technology with pharmaceutical companies in the regions most at risk; increasing drug supply through the World Health Organization; and providing local training in prevention, early diagnosis, treatment and surveillance. We also address policy issues with governments in different nations to ensure that sound strategies for MDR-TB management are in place, and to work towards stopping the spread of this disease.


Innovation in the treatment of disease has been Eli Lilly and Company's animating purpose since our founding more than 130 years ago. The Lilly MDR-TB Partnership expands that tradition of innovation to confront a global public-health crisis that no single group, nation, or sector of society can take on by itself. I invite you to browse our website for details on the MDR-TB challenge - and our response.

 

 

VideosVideos

News

IHF launches online TB manual toolkit for hospital decision makers

WMA launches online
TB refresher course


Lilly Transfers Capastat® License and Trademark to VIANEX SA

The Lilly TB Drug Discovery Initiative Announces New Collaborator

Photo Award 2009: Images to Stop TB

Lilly launches MDR-TB programs in Brazil

Lilly_ICN.BCLC.Award
Lilly_ICN.BCLC.premio
Lilly_ICN.BCLC.prix

Scaling Up the Global Nursing Workforce to Fight Multidrug-Resistant Tuberculosis

New Toolkit Helps Chinese Companies Tackle TB Head On
(中文 Chinese)

Bam! Kapow! Figo
scores a goal against tuberculosis in a new comic book
(Português) (Français)

New toolkit boosts South African companies response to TB threat


Tuberculosis (TB) kills close to 2 million people every year

4500 people will die of TB by the end of today -- most of whom are in their most productive working years (ages 15 to 54)

More than 2 billion people, equal to one-third of the world's population, are infected with TB bacilli, the microbes that cause TB

12 million people worldwide with HIV/AIDS-TB co-infection

One-third of AIDS patients die of TB, making TB the leading cause of death among AIDS patients

Nearly 500,000 of the 9.2 million new cases of TB every year are multidrug-resistant

China and India account for half the world's MDR-TB cases

Highest MDR-TB incidences are in countries of the former Soviet Union

TB and MDR-TB are curable

The goal of the partnership is to treat more 20,000 MDR-TB patients by 2010

A single person infected with MDR-TB may unknowingly infect, on average, up to 15 other people

About one-third of the world's population carries a latent strain of tuberculosis

Two billion people are infected with TB bacilli worldwide -- 1 in 10 will become sick with active TB

 

Partners spotlight

partners
ICN, IFRC, IHF, WMA Interprofessional Training (2007)
Cape Town, South Africa
 

Copyright© 2008 Eli Lilly and Company | Privacy
footer